कोशिश गोल्ड - मुक्त
Championing PAY PARITY
BioSpectrum Asia
|March 2024
Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.
GlaxoSmithKline's (GSK) appointment of Emma Walmsley as CEO in 2016 made headlines for more than one reason. Notably, she became the first woman to lead a major pharmaceutical company in big pharma history. Her appointment also drew attention because she was paid less than her male predecessor. Her starting base salary of £1.0 million for 2017 was still lower than that of her predecessor, Andrew Witty, who earned £1.11 million in 2016. An EP Vantage analysis finds that her starting base salary is the lowest awarded to the existing generation of global big pharma chiefs. GSK defended the decision to pay her less based on her experience, pointing out that this would be her first chief executive role.
Years later, she remains the only woman CEO of a big pharma company and the issues of pay parity persist. This highlights the sad affairs of women's representation in leadership roles and unequal pay.
There have been numerous reports highlighting the lack of pay parity in the life sciences sector. According to a report from the World Health Organization, women worldwide still face a 24 per cent salary differential compared to men across the healthcare sector. This figure hasn’t budged much since the early 2000s. The report examined data from 54 countries across all geographic and income regions. The study found a 24 per cent gap after factoring in age, education, and number of working hours.
Another report by Arjuna Capital and Proxy Impact highlighted that the healthcare industry is reported to have the fifth widest adjusted gender pay gap out of 22 industries, at 5.7 per cent as reported by Glassdoor. That gap has improved by 1.5 per cent since 2015. Biotech and pharma are reported to have the smallest adjusted gender pay gap at 2.2 per cent improving 0.8 per cent since 2015.
यह कहानी BioSpectrum Asia के March 2024 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
BioSpectrum Asia से और कहानियाँ
BioSpectrum Asia
Alphamab Oncology appoints Fei Wang as Chief Financial Officer
Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market
DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
PHCbi introduces LiCellGrow Cell Expansion System
PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences
CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala
Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Argo Biopharma ropes in Dr Gena Wang as CFO and CSO
China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust
The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Korea designs model for accurate and scalable drug-drug interaction prediction
A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.
1 min
BioSpectrum Asia April 2027
Listen
Translate
Change font size
